Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity

Brandon Kayser, Marie Lhomme, Edi Prifti, Carla da Cunha, Florian Marquet, Florian Chain, Isabelle Naas, Véronique Pelloux, Maria-Carlota Dao, Anatol Kontush, et al.

To cite this version:


HAL Id: hal-02135899
https://hal.sorbonne-universite.fr/hal-02135899
Submitted on 3 Jul 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity

Brandon D. Kayser,* Marie Lhomme,†,‡ Edi Prifti,*†,‡ Carla Da Cunha,* Florian Marquet,* Florian Chain,§ Isabelle Naas,¶ Véronique Pelloux,* Maria-Carola Dao,* Anatol Kontush,‖ Salwa W. Rizkalla,* Judith Aron-Wisnewsky,*,‖ Luis G. Bermúdez-Humarán,§ Fiona Oakley,§ Philippe Langella,§ Karine Clément,*‖,1 and Isabelle Dugail*,2

Nutraomics Team and 1Integrative Biology of Atherosclerosis Team, INSERM, Unité 1166—Sorbonne Université, Paris, France; 1ICANalytics Team and; 2Integromics Team, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France; 3Micalis Institute, Institut National de la Recherche Agronomique (INRA)—AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France; 1Nutrition Department, Centre de Recherche en Nutrition Humaine (CRNH)—Ile de France, Pitié-Salpêtrière Hospital, Assistance Publique—Hôpitaux de Paris (AP—HP), Paris, France; and 2Newcastle Fibrosis Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

ABSTRACT: Lipidomic techniques can improve our understanding of complex lipid interactions that regulate metabolic diseases. Here, a serum phospholipidomics analysis identified associations between phosphatidylglycerols (PGs) and gut microbiota dysbiosis. Compared with the other phospholipids, serum PGs were the most elevated in patients with low microbiota gene richness, which were normalized after a dietary intervention that restored gut microbial diversity. Serum PG levels were positively correlated with metagenomic functional capacities for bacterial LPS synthesis and host markers of low-grade inflammation; transcriptome databases identified PG synthase, the first committed enzyme in PG synthesis, as a potential mediator. Experiments in mice and cultured human-derived macrophages demonstrated that LPS induces PG release. Acute PG treatment in mice altered adipose tissue gene expression toward remodeling and inhibited ex vivo lipolysis in adipose tissue, suggesting that PGs favor lipid storage. Indeed, several PG species were associated with the severity of obesity in mice and humans. Finally, despite enrichment in PGs in bacterial membranes, experiments employing gnotobiotic mice colonized with recombinant PG overproducing Lactococcus lactis showed limited direct contribution of microbial PGs to the host. In summary, PGs are inflammation-responsive lipids indirectly regulated by the gut microbiota via endotoxins and regulate adipose tissue homeostasis in obesity.—Kayser, B. D., Lhomme, M., Prifti, E., Da Cunha, C., Marquet, F., Chain, F., Naas, I., Pelloux, V., Dao, M.-C., Kontush, A., Rizkalla, S. W., Aron-Wisnewsky, J., Bermúdez-Humarán, L. G., Oakley, F., Langella, P., Clément, K., Dugail, I. Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity. FASEB J. 33, 4741–4754 (2019).

www.fasebj.org

KEY WORDS: phosphatidylglycerol synthesis · adipocyte lipolysis · lipidomic profiling · serum phospholipidome

Altered lipid homeostasis is central to chronic metabolic disorders, including obesity, type 2 diabetes, liver, and cardiovascular diseases. These diseases are also commonly characterized by low-grade inflammation, a well-established component of their pathophysiology. Going beyond standard clinical measurements of triglycerides and

ABBREVIATIONS: BMI, body mass index; CRP, C-reactive protein; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, Δ9-cis; DOPG, 1,2-dioleoyl-sn-glycero-3-phosphoether (1′,2′-di-O-acylglycerol); EpiAt, epididymal adipose tissue; HGC, high gene count; KEGG, Kyoto Encyclopedia of Genes and Genomes; KO, KEGG Orthologs; LGC, low gene count; LL-pgsA, recombinant strain of Lactococcus lactis over-expressing PgsA; LL-WT, L. lactis MG1363 containing pGK-empty plasmid; NC, normal chow; OB, obese; OW, overweight; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PGS1, phosphatidylglycerol phosphate synthase; PIA, N6-phenylisopropyl adenosine; SO, severe obesity

1 Correspondence: INSERM UMR S1166, Sorbonne University, Nutriomics Team, 43-83 Boulevard de l’Hôpital, IEMB, 75013 Paris, France. E-mail: karine.clement@inserm.fr

2 Correspondence: INSERM UMR S1166, Sorbonne University, Nutriomics Team, 91 Boulevard de l’Hôpital, 75013 Paris, France. E-mail: isabelle.dugail@inserm.fr
cholesterol, a better understanding of the lipidome may uncover novel pathways of these diseases and identify predictors of their progression (1). Phospholipids are one of the most diverse human lipid classes (2), yet their roles outside of membrane lipids are only partially understood.

Phospholipids are major structural components of cells and lipoproteins, and alterations in specific phospholipid classes are implicated in the dysregulation of cellular responses such as insulin resistance (3). Going beyond membranes, serum phospholipids are affected by metabolic disorders including overweight (OW) or obesity (4), diabetes (5), and nonalcoholic fatty liver disease (6). These amphiphilic lipids can contribute to disease by altering the structure-function relationship of lipoproteins (7) or as endocrine signaling molecules (8). Along these lines, our team has identified altered circulating phospholipids with nonalcoholic steatohepatitis in severe obesity (SO) (9) as well as improvements in these profiles following bariatric surgery, which results in metabolic and inflammatory improvements (10).

The gut microbiota has emerged as an important factor at the interface of nutrition and host metabolism and inflammation. This symbiotic relationship involves direct and indirect signals from gut microbes that can shape the immune system, and a growing list of these bacteria-derived molecules includes trimethylamine or trimethylamine N-oxide (11), hippurate (12), and LPS (13). Increased exposure to LPS in obesity has been termed metabolic endotoxemia and may be an important contributor to chronic low-grade inflammation. More globally, thanks to next generation sequencing, loss of microbial gene richness in the gut is now recognized as a condition associated with chronic inflammation. This symbiotic relationship involves direct and indirect signals from gut microbes that can shape the immune system, and a growing list of these bacteria-derived molecules includes trimethylamine or trimethylamine N-oxide (11), hippurate (12), and LPS (13). Increased exposure to LPS in obesity has been termed metabolic endotoxemia and may be an important contributor to chronic low-grade inflammation. More globally, thanks to next generation sequencing, loss of microbial gene richness in the gut is now recognized as a condition associated with chronic inflammation and degraded metabolic health (14–16).

Based on our previous findings that circulating phospholipids are altered in the hepatic portal system of nonalcoholic steatohepatitis patients with morbid obesity (9), a condition highly associated with gut dysbiosis (17), the aim of the current study was to directly investigate the links between gut microbiota status, low-grade inflammation, and serum phospholipids in patients with obesity.

**MATERIALS AND METHODS**

**Study population**

Patients with obesity were followed at Pitié-Salpêtrière Hospital (Nutrition Department, Centre de Recherche en Nutrition Humaine Ile de France). First, a group of patients with moderate obesity (NCT01314690; [clinicaltrials.gov](https://clinicaltrials.gov/)) consisted of 49 participants (8 males, 41 females) who were OW (n = 11) or obese (OB; n = 38). The intervention consisted of a 6-wk period on a low-calorie diet enriched with soluble fiber, high protein intake, and low glycemic index carbohydrates as well as a 6 wk weight stabilization phase. Further details of this study have been previously published (14, 18). Baseline measurements from a group of patients with SO, consisting of 63 women, were included in some analyses and have also been previously described (NCT01454232; [clinicaltrials.gov](https://clinicaltrials.gov/)) (10).

**Study approval**

Clinical investigations were authorized by the Committees for the Protection of Persons at Hôtel Dieu Hospital, and all participants gave written and informed consent. For gnotobiotic mice, all procedures previously described were carried out according to European Community Rules of Animal Care and with authorization (3441-2016010614307552) from the French Ministry of Research. For LPS-treated mice, experiments were approved by Newcastle University’s Ethical Review Board. Animals were maintained as specific pathogen free according to the Federation for Laboratory Animal Science Associations Guidelines. Work was carried out under project and personal licenses approved by the UK Home Office.

**Targeted lipidomics**

Targeted lipidomics analysis of phospholipids was performed on lipid extracts from serum by HPLC tandem mass spectrometry using both negative- and positive-ion modes and selective multiple reaction monitoring, which have been previously detailed (7, 10). Phosphatidyglycerols (PGs) were analyzed in positive-ion mode to distinguish from isobaric bis(monoacylglycerol) phosphate (19). Human samples and high-fat diet (HFD)-fed and germ-free mice were analyzed with the above method, whereas all other samples were analyzed using a modified protocol that increased the number of detectable PG species and is described in the Supplemental Data. External standards for the different phospholipid classes were used for calibration curves (Avanti Polar Lipids, Alabaster, AL, USA). The number of PG species quantified in a given experiment varied as a function of sample type (serum, culture medium, or bacterial cell lysate). Human peripheral blood mononuclear cells were isolated fromuffy coats of healthy donors over a Lymphoprep gradient (Stemcell), and monocytes were purified by magnetic cell sorting using anti-CD14-coated beads (Miltenyi Biotech, Bergisch Gladbach, Germany).

**Fecal metagenomic analysis**

Total fecal DNA was extracted and sequenced on a high-throughput ABI SOLiD (Thermo Fisher Scientific, Waltham, MA, USA) sequencer. Reads were cleaned for quality and origin, mapped to the 3.9 million gene reference catalog (20), and normalized by nucleotide length. Observed gene richness was calculated after downsizing the data to 7 million reads. Meta-

**Analysis of public databases**

Data for the Gene-Tissue Expression database (23) were downloaded from the Harmonizome project (Tissue Sample Gene Expression Profiles; [harmonizome.org](http://harmonizome.org)) and log transformed (24). The microarray data from the studies of Wynn et al. (25) (with samples restricted to survivors) and Calvano et al. (26) (excluding the 2 h time point) were downloaded from the Gene Expression Omnibus (27) with accession numbers GSE26378 and GSE3284, respectively. See Supplemental Data for details.

**Mouse experiments**

C57BL/6j mice were 8 to 12 wk old were used in all studies [dietary studies, antibiotic treatment, and lipid
micelles 1,2-dioleoyl-sn-glycero-3-phosphoglycerol, Δ9-cis (DOPG) injections) and were provided by Janvier Labs (St. Berthevin, France) unless otherwise stated. Mice were housed in the UMS28 facility at la Pitié-Salpêtrière Faculty of Medicine under specific pathogen-free conditions at a constant temperature (23°C) with ad libitum access to food and water. All protocols received agreement from the local ethical committees.

**OB mouse models**

Mice were made OB using 60% HFD (D12492i; Research Diets, New Brunswick, NJ, USA). ob/ob mice which were 6 to 8 wk old on a C57Bl6 background were obtained from Janvier Labs.

**LPS infusion**

Mice obtained from Harlan Laboratories (Indianapolis, IN, USA) were treated with a single intraperitoneal injection of saline or Pure LPS (300 μg; InvivoGen, San Diego, CA, USA). One hour before and 6 h after LPS injection, 1 group also received an intraperitoneal injection of IKK-2 Inhibitor VI (5 mg/kg; MilliporeSigma, Burlington, MA, USA).

**Exogenous administration of DOPG in mice**

Purified DOPG and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, Δ9-cis (DOPE) (Avanti Polar Lipids) in chloroform were evaporated and reconstituted into 20% intralipid (1141; MilliporeSigma) to obtain 15 μg/25 μl for DOPG and 300 μg/25 μl for DOPE. Then, intralipid concentration was adjusted to 5% with PBS. Lean mice received 100 μl of 5% intralipid for vehicle or DOPG/DOPE liposomes as intraperitoneal injection. The ob/ob mice were intraperitoneally injected with DOPG-only liposomes, which were prepared similarly, except that DOPE was omitted. Composition of 5% intralipid solution is 50 μg/μl triacylglycerol (from soybean oil), 3 μg/μl phosphatidylcholine (PC; from egg phospholipids), and 5.5 μg/μl glycerol as indicated by the manufacturer.

**Microbiota depletion with antibiotics**

For antibiotic treatment, a cocktail consisting of ampicillin (7.5 mg/ml), neomycin (10 mg/ml), metronidazole (10 mg/ml), vancomycin (5 mg/ml), and amphoterin-B (0.1 mg/ml) were given by oral gavage (0.01 ml/g weight) once per day for 10 d.

**Germ-free mice**

Serum samples used to compare PG levels in conventional and germ-free female Swiss Webster mice were a generous gift from Robert Caesar (Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden) and Fredrik Bäckhed (Wallenberg Laboratory, Institute of Medicine, University of Gothenburg) and collected from mice maintained as previously described (28).

**Gnotobiotic mice**

Lactococcus lactis MG1363 containing pGK-empty plasmid (LL-WT) or pGroESt-psgA (LL-PsgA) plasmids were generated using previously described Materials and Methods (29) detailed in the Supplemental Data. Animals were housed in Anaxem-Micalis germ-free rodent facility (INRA, Jouy-en-Josas, France) and were orally administered with L. lactis MG1363 containing LL-psgA or LL-WT (1 × 10⁹ CFU in 200 μl of sterile PBS per gavage) for 4 d.

**Lipolysis**

Adipose tissue samples were obtained from elective liposuction in 8 healthy non-OB subjects [44.3 ± 4.6 yr, body mass index (BMI) 23.0 ± 1.1 kg/m²]. After overnight wash-out in complete DMEM supplemented with 10% fetal calf serum, adipose tissue fragments were incubated in fresh medium for 24 h with indicated concentrations of 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DPPG; Avanti Polar Lipids) using ethanol as a vehicle. Glycerol release into the medium was recorded during the last 2 h after adding fresh phenol red-free medium containing 2% bovine serum albumin and DPPG. Glycerol concentration in culture medium was measured using a Colorimetric Assay Kit (Cayman Chemicals, Ann Arbor, MI, USA) and normalized to cell protein content. The schematic representations of regulation of adipose tissue lipolysis by activating of inhibiting GPCRs and their ligands were as follows: PI (MilliporeSigma), an adenosine analog acting through G₁-coupled adenosine receptor; adenosine deaminase (ADA; MP Biomedical, Santa Ana, CA, USA), which degrades extracellular adenosine; isoproterenol (ISO; MilliporeSigma), a nonspecific β-adrenergic agonist acting through G₂ and AM6445, an antagonist of G₁-coupled CB1 receptor (gift from Dr. P. Degrace, Université de Bourgogne, Dijon, France).

**Gene expression and mRNA quantification**

mRNAs were extracted from frozen tissue using commercially available kits (Qiagen, Venlo, The Netherlands) and reverse transcribed, and cDNA were quantified by real-time RT-PCR using qPCR MasterMix Plus for SYBG Green (Eurogentec, Liége, Belgium). Primer efficiency was assessed using standard curves. Expression data were evaluated using the ΔΔCt method. Glyceraldehyde-3-phosphate dehydrogenase and 18S mRNA were used for normalization.

**Statistical analysis**

Statistical analyses were performed in the R Language and Environment with packages listed in brackets. Lipidomics data were log₂ transformed for all statistical tests to mitigate skewness, although these data are sometimes presented on the raw scale to enhance interpretation. Spearman correlation was used for bivariate associations (base R). Two-sample comparisons were tested using Welch’s t test (base R). Both 1- and 2-way ANOVA were used for multiple group comparisons [car]. Longitudinal data were analyzed using mixed effects models with random intercepts for subject (lme4, car, multicomp). Following a significant interaction, simple effects were tested using Welch’s t tests. Following a significant main effect, post hoc comparisons were made using generalized linear hypothesis tests with the Bonferroni-Holm adjustment.

**RESULTS**

**Gut dysbiosis is associated with increased serum PGs**

Targeted lipidomics can provide deep profiling of specific lipid groups. As such, our method successfully quantified low-abundance classes such as PGs, phosphatidylserines, and phosphatidic acids in human and mouse serum, in
addition to highly abundant PCs and phosphatidylethanolamines (PEs) (Fig. 1A, B). Importantly, the relative abundance of each phospholipid class was relatively similar between humans and mice (Fig. 1A, B). For example, PG(34:1), PG(36:2), and PG(36:1) together comprised 75% of the total PG and shared the same rank order across species, validating the use of clinical and animal models to study these phospholipids.

We have examined the relationship between the serum phospholipidome and the gut microbiome in OW/OB subjects (14). Almost half of the phospholipid species in serum, distributed across several classes, inversely correlated with gut microbiome richness, indicating intricate links ($\rho$ between $-0.3$ and $-0.6$; Fig. 1C). A high correlation between PG and PE, both highly abundant phospholipids in microbes, was observed (Supplemental Fig. S1). Dichotomizing patients into high gene count (HGC) and low gene count (LGC) at a 480,000 gene threshold has previously revealed increased metabolic risk and low-grade inflammation in LGC individuals (14, 15). PGs were the most increased phospholipid class and elevated by $-50\%$ in LGC subjects (Fig. 1D, E). At the class level, other phospholipids were also elevated in LGC group, including PE. In agreement with the high correlation between PG and PE, many PE species were also elevated in the LGC group (Supplemental Fig. S2A). Conversely, a fiber-enriched hypocaloric diet, which improves metagenomic richness (14), resulted in normalization of serum PGs in LGC individuals to that of HGC (Fig. 1F). PE concentrations showed similar evolution, albeit that PE levels also declined in HGC individuals (whose richness slightly decreased with weight loss (14) (Supplemental Fig. S2B). Relative to baseline, diet-associated changes in serum PG concentrations were more marked in the LGC group, with a greater effect achieved during active weight loss than weight stabilization (Fig. 1G). Thus, both cross-sectional and longitudinal studies identified a strong link between gut dysbiosis and altered PG and PE phospholipids.

**Serum PGs are associated with metabolic endotoxemia potential and low-grade inflammation**

First focusing on metagenomic abundance of KO reflecting bacterial PG metabolism, PG synthesis genes were not correlated with serum PG levels (adjusted $P > 0.05$; Fig. 2A), indicating equal potential for PG synthesis among bacterial communities irrespective of overall gene richness. However, an untargeted analysis of metagenomic functional capacity revealed several KEGG modules that were significantly correlated with serum PG levels (all adjusted $P < 0.01$; Fig. 2B). Of particular note were the positive associations with 2 modules involved in LPS biosynthesis. In this analysis, PE levels associated non-significantly with the PE synthesis module (Supplemental Fig. S2C, D).

This observation prompted us to examine the associations between PG and PE phospholipid levels and low-grade inflammation in an extended patient sample that included the OW/OB subjects and a patient cohort with SO (Supplemental Table S1). Serum PGs were positively correlated with serum IL-6 (Fig. 2C) and C-reactive protein (CRP; Fig. 2D), and inversely associated with the anti-inflammatory adipokine adiponectin (Fig. 2E). Importantly, the correlations between PG and IL-6 and adiponectin remained after adjustment for percent body fat, percent android fat, age, and fasting triglycerides using multiple linear regression (Fig. 2F). These data suggest that PGs may be inflammation-responsive lipids that are elevated in gut dysbiosis. Regarding serum PEs, we found no association with CRP ($\rho = -0.02$), negative correlation with IL-6 ($\rho = -0.20$, $P < 0.05$), and positive correlation with adiponectin ($\rho = 0.32$, $P < 0.001$), which is inconsistent with links to gut dysbiosis and related inflammation.

**PGs are induced by endotoxin and inflammation**

The Gene-Tissue Expression project was queried to home in on the source of elevated PGs. Phosphatidylglycerol phosphate synthase (PGS1), the first committed enzyme in PG synthesis, is expressed across numerous tissues but was most highly expressed in whole blood (Fig. 2G), even greater than that of lung, where PGs is an important component of surfactant (30–32). The Gene Expression Omnibus database was also searched for experiments in which PGS1 expression was increased. In a data set of children admitted to the hospital with sepsis (25), whole blood PGS1 expression was markedly increased (4-fold increase, adjusted $P < 0.001$; Fig. 2H, top). Another study (26) experimentally corroborated inflammation-related PGS1 regulation, in which PGS1 expression was increased 3.5-fold after intravenous LPS infusion (adjusted $P < 0.001$; Fig. 2H, bottom). Interestingly, PGS1 was regulated independently of the other genes in the PG-synthesis pathway, with the exception of LPZGT1 (adjusted $P < 0.001$; Fig. 2H, bottom). Changes in expression of genes involved in PE synthesis were not consistent across the 2 data sets (Supplemental Fig. S2E). Next, gene coexpression networks for PGS1 were used to uncover its molecular regulation. This analysis revealed marked agreement between the 2 data sets, and PGS1 expression was directly related to pathogen-associated molecular pattern recognition [e.g., Toll-like and Nod-like receptor signaling (Fig. 2J)]. Given the lack of association between PE and markers of inflammation, a search was not performed for data sets reporting altered expression of PE synthesis genes.

**Rodent models identify the host as the primary source of circulating PGs**

PGs are considerably enriched in bacterial membranes relative to eukaryotic cells (33, 34), leaving open the possibility that the gut microbiota can contribute directly to circulating PGs in addition to the above documented inflammation-dependent PG induction. Therefore, we engineered a “super PG producing” recombinant strain of L. lactis that overexpresses the bacterial homolog of PGS1,
PgsA (LL-pgsA), which were successfully enriched with PGs compared with the wild-type L. lactis (LL-WT; Fig. 3A and Supplemental Fig. S3). Compared with gnotobiotic mice colonized with the LL-WT strain, female mice receiving the LL-pgsA strain had a statistically significant 18% increase in total serum PG (Fig. 3B). Across similar gnotobiotic status and comparable colonization efficiencies (data not shown), male mice did not respond to LL-pgsA gavage by increasing PG serum concentrations, but females did. The largest increase in females occurred...
with saturated species, namely PG(32:0), PG(34:0), and PG(36:0) (Fig. 3C); however, these are low abundance species, and therefore the effect on total PG was modest.

The direct contribution of the gut microbiota to serum PG levels was also tested following a microbiota-depleting course of antibiotics that recapitulates the germ-free
phenotype without altering body weight (Supplemental Fig. S4A–C). In such microbiota-depleted mice, neither total PG nor individual PG species were altered with normal chow (NC) or HFD (Fig. 3D and Supplemental Fig. S4D), and PE slightly declined (Supplemental Fig. S4F, G). Serum PG and PE levels were both unaltered by germ-free housing of mice (Fig. 3E and Supplemental Fig. S4H). Thus, though gut microbes can increase host PG levels directly under certain conditions, at least in female mice, PG production by the host appears to be the primary contributor to circulating PGs.

**Direct link from inflammation to PG synthesis**

To directly demonstrate regulation of PG synthesis by inflammation, mice were treated with intraperitoneal LPS with or without an IKK2-inhibitor. LPS injection doubled total serum PG, which was fully blunted by the inhibitor (Fig. 4A, B). To validate this effect in endotoxin-sensitive human cells, we treated primary human monocyte-derived macrophages, either in the naive state (M0) or after M2 polarization (M2), with a broad range of LPS doses. After 24 h, both M0 and M2 demonstrated a curvilinear dose response to the release of PG into the culture medium, with a more responsive effect in M2 cells (Fig. 4C, D).

The expression of PGS1 mRNA across a number of metabolic tissues was quantified in HFD-fed OB mice, which developed inflammation and endotoxemia. In control mice, PGS1 expression in adipose tissue depots and intestine was greater than in liver (Fig. 4E and Supplemental Fig. S4F). Therefore, gut microbes can increase host PG levels directly under certain conditions, at least in female mice, PG production by the host appears to be the primary contributor to circulating PGs.

**Exogenous PGs promote gene expression related to adipose tissue remodeling**

We next investigated whether PG could exert metabolic effects by applying an acute treatment with exogenous PG
and PE, both highly correlated in human serum (Supplemental Fig. S1). Lean chow-fed mice received a daily dose of DOPG and DOPE (0.5 and 10 \( \mu \)g/g, respectively) in a 5% intralipid vehicle, injected intraperitoneally for 5 consecutive days. PG treatment increased 187 and decreased 127 adipose tissue genes compared with vehicle controls (false discovery rate, 5%; Supplemental Table S2). Pathway analysis indicated significant alterations in genes related to the regulation of TLR by endogenous ligands and tissue remodeling (Fig. 5A). Extracellular matrix-related genes included Col4a5, Col4a6, Col6a6, and Fbln2, all related to structural components, and M2-macrophage markers such as Mgl2 (Cd103b), Clec10a (Cd301), and Cd163 (Fig. 5B and Supplemental Table S2). The absence of changes in body weight, food intake, or fat mass (data not shown) suggested direct PG effects. PG potential on adipose tissue remodeling was also observed in an OB setting, as treatment of ob/ob mice with DOPG alone or vehicle confirmed the PG-induced increases in M2-related genes (Fig. 5C). No significant effects on M1-related genes were observed (data not shown). As a whole, these data indicate that PG may favor adipose tissue remodeling and maintenance of homeostasis in obesity.

**PGs inhibit adipose tissue lipolysis**

We next explored if PG might affect adipose tissue lipid metabolism, and we therefore examined whether PGs would modulate lipolysis. Intracellular cAMP, regulated by GPCR, is critical to adipocyte lipolysis (Fig. 6A). Human adipose tissue explants were highly responsive to lipolytic modifiers (Fig. 6B). We observed that treatment of adipose tissue fragments with DPPG up to 1 \( \mu \)M dose-dependently decreased glycerol release in basal conditions.
Importantly, DPPG was still able to reduce glycerol release when isoproterenol was combined with N6-phenylisopropyl adenosine (PIA), an adenosine receptor agonist (Fig. 6D), but had no effect in the presence of the b-adrenergic agonist isoproterenol, alone (Fig. 6E), indicative of an inhibitory G protein (Gi) mediated effect of DPPG rather than inhibition of a stimulatory G protein (Gs) dependent formation of cAMP or activation of cAMP catabolism by phosphodiesterases. Indeed, a dose-dependent response to PIA in the presence or absence of increasing DPPG concentrations (Fig. 6F) indicated a left-shifted dose-response curve. Glycerol release was almost totally inhibited with 40 nM PIA in the absence of DPPG, whereas 20 nM PIA was sufficient in the presence of 0.2 μM DPPG. We found no evidence that PG could inhibit lipolysis indirectly via endogenous antilipolytic molecules. Glycerol release remained suppressed by DPPG despite depletion of extracellular adenosine antilipolytic by adenosine deaminase (Fig. 6G) or addition of AM6445, a CB1 receptor antagonist (Fig. 6H). Similarly, DPPG did not stimulate extracellular release of lactate, another antilipolytic metabolite (Fig. 6I). Together, these data suggest that exogenous PGs may favor the maintenance of adiposity by modulating adipocyte lipid mobilization.

**DISCUSSION**

This report sheds new lights on the metabolic role of PGs, a poorly understood phospholipid class. Our work follows recent lipidomic studies that reported altered circulating

**PG levels associated with adiposity in mice and humans**

Total serum PG was ~50% higher in HFD-induced OB mice compared with NC controls, a difference which exceeded the other elevated phospholipid classes, PI, PC, and PE (Fig. 7A). In HFD mice, where PG species homogenously increased (Fig. 7B), PE species were evenly increased or decreased depending on chain length and unsaturation (Supplemental Fig. S5). PG was also the most affected phospholipid class with increasing obesity grade in humans, as patients with SO (mean percent body fat, 49.9±3.6) had ~3-fold higher levels of serum PG compared with OW/OB (mean percent body fat, 39.4±6.6) (Fig. 7C), with all individual PG species affected (Fig. 7D). Importantly, PG elevation with body fat occurred in generally normolipidemic patients, as fasting triglycerides and cholesterol were not increased in SO compared with OW/OB (Supplemental Table S1). Furthermore, a positive correlation across the range of BMI was observed for PG concentrations (r = 0.63, P < 0.001) but not PC (Fig. 7E), indicating that the PG/corpulence relationship was not simply because of globally elevated phospholipids. Notably, PE declined with obesity severity as well as LPC (Fig. 7C) and negatively associated with BMI (Fig. 7E). Thus, in mice as well as humans, elevated PGs are a signature of increased adiposity, which corroborates PG potential to preserve adipose tissue expandability in the presence of catabolic inflammation.
PG concentrations in different metabolic diseases, including diabetes and nonalcoholic steatohepatitis (5, 9, 10). However, this is the first study to demonstrate a relationship between gut dysbiosis and low-grade inflammation in the regulation of serum PG levels in obesity. Moreover, we demonstrated that PGs are induced by endotoxin and act in a negative feedback loop in inflammation to modulate adipose tissue response in obesity.

Figure 6. PG inhibits in vitro adipose tissue lipolysis. A) Schematic representation of regulation of adipose tissue lipolysis by activating of inhibiting GPCRs and their ligands: PIA (MilliporeSigma), ADA (MP Biomedical) ISO, and AM6445. B–H) Relative glycerol release as a lipolytic index of adipose tissue samples treated for 4 h with the indicated effectors and Dipalmitoyl-PG (PG). Relative glycerol release is calculated from values corrected for tissue protein content. Bars are the mean ± SEM from 4 to 8 independent experiments with subcutaneous adipose tissue samples of non-OB donors. B) Pairwise comparisons by Student’s t test between effectors. C–H) Significance of PG effects in dose response curves are tested by Kruskal-Wallis or Friedman test. F) Dose response to PIA in the presence of PG (a representative experiment is shown). I) Lactate release into the culture medium. Values are means of triplicate dishes. *P < 0.05, **P < 0.005, ***P < 0.001.

Low-grade inflammation is a general comorbidity in metabolic diseases, likely initiated by diverse alterations linked to fatty acid excess, tissue accumulation of reactive oxygen species, gut microbiota imbalance, and presumably other factors such as genetic susceptibility. Intricately linked within each other, it is impossible to identify a single cause to metabolic inflammation, but recent studies have depicted a prominent contribution of gut microbiota dysbiosis. Low metagenomic richness is associated with altered metabolic and inflammatory conditions (15, 35), but the molecular mechanisms behind these links are unclear. To this end, we report profound alterations in the circulating phospholipidome of patients with low metagenomic richness, most notably PG, PE, and PI. Though the current report focused on PGs, an otherwise poorly understood phospholipid, the relationship between the microbiota and other
phospholipid classes offers important future work. Serum phospholipids correlate with increasing BMI in large epidemiologic cohorts (4), and our findings suggest that the gut microbiota may be an important contributor to these changes. However, other inflammatory mediators, including other phospholipids, cannot be definitively excluded from this regulatory pathway. Furthermore, our study did not include normal weight individuals. Whether changes in gut microbiota in healthy controls would affect PG levels and long-term metabolic risk requires an independent investigation.

We found that PGs were positively associated with microbiomes enriched with endotoxin-synthesis genes and associated with markers of inflammation. Furthermore, elevation of PG levels by LPS was directly demonstrated in mice and human cells. Though PG synthesis is ubiquitous, it might be particularly important in endotoxin-responsive leukocytes. That PGS1 expression is increased in adipose tissue of OB mice, which become infiltrated by an abundance of macrophages and other leukocytes (36), corroborates the important role of inflammation in the control of circulating PG levels. Notably, previous studies in mice have demonstrated that the gut microbiota regulates adipose tissue macrophage activation and recruitment via TLR signaling (28, 37). In line with those studies, increased serum PGs in mice following HFD-induced obesity are found with increased PGS1 expression in adipose tissue. The primary mechanism for inflammation-dependent increased PG levels appears to be due to increased synthesis (as indicated by increased PGS1 expression) rather than degradation of cardiolipin, a potential store of PG, where even under severe cardiolipin degradation PG levels are unaltered (38). Given that numerous inflammatory pathways are up-regulated in obesity, an important question for future studies is to determine if TLR is a required inflammatory pathway that triggers PG synthesis (39). Though PE levels were initially related to gut dysbiosis, PE abundance at the class level was not consistently associated with markers of inflammation in our study.

We also provided evidence that elevated PG levels may participate in the defense of adipose tissue function in the context of low-grade inflammation. Short-term treatment in mice demonstrated that PGs can induce transcriptional regulation of M2-like macrophage polarization genes in adipose tissue. PGs were also found to reduce adipose tissue lipolysis ex vivo, thereby potentially moderating fatty acid leak from OB adipose tissue. The strong association between PGs and adiposity in mice and humans is consistent with PG being a signal for the preservation of adipose tissue stores. Consistent with the characterized anti-inflammatory effect of PG in the lung (31, 32), the

![Figure 7. Serum PG concentrations correlate with increasing obesity grade in mice and humans. A, B) Differences in serum concentrations of total phospholipid classes (A) or individual PG species (B) between mice fed HFD vs. NC (10 mice/group). C, D) Comparison of phospholipid concentrations (C) or individual PG species (D) in 49 patients with OW/OB vs. 63 with SO or morbid obesity (MO), respectively. E) Correlation between serum PG and PC across patient body mass index (BMI; circles are OW/OB, n = 49). Triangles are those with MO. *P < 0.05, ** P < 0.01, *** P < 0.001 compared with the corresponding control within the same phospholipid class. Bar height is mean, and error bars ± SEM. E) Correlations between total serum phospholipid classes and BMI across subjects with OW/ OB and SO.](image-url)
anti-lipolytic and proremodeling actions of PG indicate that these phospholipids may favor an overall protective effect on adipose tissue remodeling. In the future, it will be important to determine whether PGs cooperate with the broader class of bioactive lipids involved in the resolution of inflammation (40), such as those derived from ω-3 polyunsaturated fatty acids that can stimulate phagocytic M2-like macrophages (41). The possibility that PGs act alongside proresolving lipids would explain the counterintuitive observation that a gut dysbiosis-related metabolite would exert beneficial metabolic actions in obesity similar to other beneficial mediators, such as resolvin D1 and IL-10, which are also elevated yet dysfunctional in obesity (42). An important next step will be to ablate the induction of PG synthesis in response to microbiota-derived inflammation in vivo.

Given that PGs are enriched in the membrane of bacterial cells (33), we initially hypothesized that microbial PGs would contribute to serum levels in the host. However, our findings on host PG51 regulation as well as those with gnotobiotic mice colonized with recombinant PG-overproducing bacteria that resulted in a sex-specific and moderate modulation of host PG levels, presumably through direct transfer of fully saturated but an otherwise rare subset of PG species (32:0, 34:0, and 36:0), indicate that this is likely a minor contributing event. Moreover, we found that serum PGs were unaltered in microbiota-depleted mice, demonstrating that host cells are the primary source of circulating PGs. Interpretation of these results, however, is limited by the fact that inoculation by a single species, L. lactis in particular, does not recapitulate the complex ecosystem of the gut microbiota. Furthermore, the sex-dependent response is unexpected.

In summary, we propose a novel PG-dependent regulatory loop in the complex relationship linking gut microbiota to host metabolism and inflammation. We demonstrate excessive PG production and release related to low-grade inflammation and gut dysbiosis, which may in turn favor continued adipose tissue expansion in the face of catabolic inflammatory signals. These findings highlight PG as a novel inflammation-related lipid actor in metabolism and emphasize the need for a deeper understanding of its role in metabolic diseases.

ACKNOWLEDGMENTS

The authors thank the nurses and technicians and, of course, the patients themselves for their invaluable contribution to this work. The authors also acknowledge Kayva Anjani (INSERM, Paris, France) for her contributions, as well as J. C. Bichet (Pitié Salpêtrière Hospital) for providing liposuction-derived adipose tissue samples. This work was supported by Agence Nationale de la Recherche (ANR MicObes), Programme Hospitalier de Recherche Clinique (PHRC Microbaria AOM10285/P100111), KOT-Ceprodi, Association Foundation Coeur et Arteres (clinical investigation), Société Française de Nutrition, and Institut Benjamin Delessert. Support was obtained from European Union’s Seventh Framework Program Metacardis under Grant HEALTH-F4-2012-305312, and Horizon 2020 Framework Program (EPoS, Grant 634413).

The European Foundation for the Study of Diabetes Albert Renold Travel Fellowship has contributed to the work of B.D.K., and Danone Research to the work of M.-C.D. and K.C. Funding from Foundation de France (to K.C.) was also obtained. MicObes Consortium collaborators: Aurélie Cotillard; Sean P. Kennedy; Nicolas Pons; Emmanuelle Le Chatelier; Mathieu Almeida; Benoit Quinquis; Nathalie Galleron; Jean-Michel Batto; Pierre Renaut; Stanislav Dusko Ehrlich; Hervé Blottière; Marion Leclerc; Tomas de Wouters; Patricia Lepage, Jean-Daniel Zucker, Joel Doré, Salwa W. Rizkalla. The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

B. D. Kayser generated the hypotheses, conducted experiments, analyzed the data, and wrote the manuscript together with K. Clément and I. Dugail; M. Lhomme conducted lipidomic analyses; E. Prifti performed bioinformatics for metagenomic data; C. Da Cunha, F. Marquet, F. Chain, and I. Naas designed and conducted the experiments; V. Pelloux designed and conducted microarray and gene expression experiments; M.-C. Dao and J. Aron-Wisnewsky performed data analysis; A. Kontush (lipidomics), S. W. Rizkalla and J. Aron-Wisnewsky (clinical investigations), L. G. Bermúdez-Humaran and P. Langella (recombinant bacteria and gnotobiotic mice), and F. Oakley (endotoxin treatments) designed and supervised the experiments; K. Clément and I. Dugail generated the hypotheses, analyzed data, and supervised the experiments and clinical investigations; K. Clément and I. Dugail are the guarantors of this work; and all authors provided critical review of the manuscript.

REFERENCES

From the given text, here is the plain text representation:


